💉 Modiblast continues to make progress towards the initiation of a first clinical trial for its in vivo personalized cancer therapy. Meet us at #SACHS_BEF in September, to learn more. Modiblast’s therapeutic approach combines two crucial factors to turn #foe into #friend. A myeloid differentiation factor fosters the creation of dendritic cell progenitor cells and #hematologicalrecovery. The patented combination with a danger signal and maturation factor drives the formation of dendritic cells. Both signals combined trigger the reprogramming of cancer blasts into dendritic cells of leukemic origin and boost the creation of healthy DC. 🇨🇭 Our CEO Helga Schmetzer will provide a corporate update to international investors at the Sachs Associates' 24th Annual Biotech in Europe Forum in #Basel from Sep 25-26. Mark your calendars 📆 ✏ ⬇ https://lnkd.in/dS37KrA2
We are pleased to announce that the 24th Annual Biotech in Europe Forum (#Sachs_BEF) will take place on the 25th - 26th of September 2024 at the Mövenpick Hotel Basel. The event will be part of the Sachs Autumn Life Sciences Week (#SALSW), which will also incorporate the 11th Annual HealthTech Investment Forum (#Sachs_HTIF).
Dieser Inhalt ist hier nicht verfügbar.
Mit der LinkedIn App können Sie auf diese und weitere Inhalte zugreifen.